Antares Pharma Inc (ATRS) Can’t Burn Your Short Portfolio. Has Another Weak Session

October 13, 2017 - By Michael Collier

Investors sentiment decreased to 2.07 in 2017 Q2. Its down 0.80, from 2.87 in 2017Q1. It is negative, as 16 investors sold Antares Pharma Inc shares while 14 reduced holdings. 36 funds opened positions while 26 raised stakes. 53.64 million shares or 13.47% more from 47.27 million shares in 2017Q1 were reported.
Ny State Common Retirement Fund owns 121,500 shares. Janney Montgomery Scott Lc has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). Moreover, Wells Fargo Communication Mn has 0% invested in Antares Pharma Inc (NASDAQ:ATRS). Arrowstreet Cap Ltd Partnership accumulated 54,000 shares. Amalgamated State Bank invested in 17,428 shares. State Board Of Administration Of Florida Retirement Systems owns 30,473 shares. 6,000 were reported by Benjamin F Edwards. Credit Suisse Ag reported 30,444 shares stake. Fuller And Thaler Asset Mgmt Inc reported 733,800 shares or 0.03% of all its holdings. State Street reported 2.03 million shares. Deutsche Natl Bank Ag reported 0% in Antares Pharma Inc (NASDAQ:ATRS). Moreover, Prelude Management Limited Liability Company has 0.03% invested in Antares Pharma Inc (NASDAQ:ATRS) for 100,330 shares. The -based Avenir Corp has invested 0.1% in Antares Pharma Inc (NASDAQ:ATRS). Raymond James Assoc, Florida-based fund reported 10,092 shares. California Employees Retirement System has invested 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS).

Since June 9, 2017, it had 1 insider purchase, and 0 insider sales for $363,272 activity.

The stock of Antares Pharma Inc (NASDAQ:ATRS) is a huge mover today! About 16.04 million shares traded or 671.15% up from the average. Antares Pharma Inc (NASDAQ:ATRS) has risen 207.14% since October 14, 2016 and is uptrending. It has outperformed by 190.44% the S&P500.
The move comes after 5 months negative chart setup for the $362.86M company. It was reported on Oct, 14 by Barchart.com. We have $2.14 PT which if reached, will make NASDAQ:ATRS worth $21.77 million less.

Analysts await Antares Pharma Inc (NASDAQ:ATRS) to report earnings on November, 8. They expect $-0.03 EPS, up 25.00 % or $0.01 from last year’s $-0.04 per share. After $-0.02 actual EPS reported by Antares Pharma Inc for the previous quarter, Wall Street now forecasts 50.00 % negative EPS growth.

Antares Pharma Inc (NASDAQ:ATRS) Ratings Coverage

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 7 analyst reports since March 9, 2016 according to SRatingsIntel. The company was initiated on Friday, September 8 by H.C. Wainwright. As per Friday, June 23, the company rating was initiated by H.C. Wainwright. Jefferies maintained the shares of ATRS in report on Monday, August 7 with “Buy” rating. Jefferies maintained Antares Pharma Inc (NASDAQ:ATRS) on Wednesday, March 9 with “Buy” rating. Piper Jaffray maintained the shares of ATRS in report on Tuesday, July 25 with “Buy” rating. Jefferies maintained the shares of ATRS in report on Tuesday, October 10 with “Buy” rating.

More important recent Antares Pharma Inc (NASDAQ:ATRS) news were published by: Fool.com which released: “Why Antares Pharma Inc Plummeted Today” on October 13, 2017, also Seekingalpha.com published article titled: “Antares Pharma: Will October Deliver A Triple Play?”, Seekingalpha.com published: “Antares Pharma (ATRS)” on October 02, 2017. More interesting news about Antares Pharma Inc (NASDAQ:ATRS) was released by: Marketwatch.com and their article: “Antares Pharma stock plunges more than 30% after FDA letter” with publication date: October 12, 2017.

Antares Pharma, Inc. is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company has market cap of $362.86 million. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. It currently has negative earnings. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.